Abstracts - PAGE Meeting (Population Approach Group Europe)

Abstracts (75)

IV-01Nikita Sakhanenko

New information-theory-based methods in the analysis of childhood development data

Thursday 14:40-16:00

IV-03Celine Sarr

Capacities of NPDE, VPC and pvcVPC at detecting model misspecification: a simulation study of a PK model showed no apparent difference

Thursday 14:40-16:00

IV-04Nina Scherer

Pharmacokinetic and Pharmacodynamic Modeling of Alirocumab and Evolocumab, two fully human monoclonal antibodies targeting PCSK9

Thursday 14:40-16:00

IV-05Emilie Schindler

PK-PD modeling of VEGF, sVEGFR-1, sVEGFR-2, sVEGFR-3 and tumor size as predictors of overall survival in axitinib-treated metastatic renal cell carcinoma (mRCC) patients

Thursday 14:40-16:00

IV-06Johannes Schropp

Development and implementation of drug-drug interaction mechanisms with target-mediated drug disposition

Thursday 14:40-16:00

IV-07Partho Sen

Identification of foods with optimal nutritional value through data mining.

Thursday 14:40-16:00

IV-08Ben Small

Changes in liver volume – a population-based approach to meta-analysis of paediatric, adult and geriatric populations

Thursday 14:40-16:00

IV-09Kevin Smart

Modeling tumor size time course in platinum resistant/refractory ovarian cancer patients treated with vanucizumab

Thursday 14:40-16:00

IV-10Mike K Smith

Model Description Language (MDL) – a standard for model communication and interoperability

Thursday 14:40-16:00

IV-11Victor Sokolov

A mechanistic PKPD model relating early asthmatic response to anti-leukotriene drug PK and biomarker levels in allergen challenge studies

Thursday 14:40-16:00

IV-12

Application of different methodologies to explain the pharmacokinetic variabilities in pregnant women: Case study of Sulindac usage

Thursday 14:40-16:00

IV-13Amaia Soraluce

Population pharmacokinetics of linezolid in critically ill patients and treatment probability of target attainment

Thursday 14:40-16:00

IV-14Konstantina Soulele

A population pharmacokinetic study of salmeterol in asthmatic patients using two dry powder inhalers

Thursday 14:40-16:00

IV-15

High-Resolution Image-based Computational Modeling of Breast Tumor Microvasculature

Thursday 14:40-16:00

IV-16Oleg Stepanov

A quantitative systems pharmacology model to explore combination efficacy of immuno-oncology compounds: Effects of CXCR2 and PD-1 inhibitions

Thursday 14:40-16:00

IV-17M. Elena Suarez Gonzalez

How delayed or missed doses influence efficacy of amoxicillin in outpatients with community-acquired pneumonia: A pharmacokinetic/pharmacodynamic simulation analysis

Thursday 14:40-16:00

IV-18Siddharth Sukumaran

A quantitative systems pharmacology model for evaluating potential drugs for treatment of asthma

Thursday 14:40-16:00

IV-19Robin Svensson

Population pharmacokinetic modeling to assess the non-linear increase in exposure following increasing doses of rifampicin

Thursday 14:40-16:00

IV-20Eva Sverrisdottir

Pharmacokinetic Metamodel of Morphine and Morphine-6-Glucuronide in Neonates and Adults

Thursday 14:40-16:00

IV-21Maciej Swat

PharmML & SO – standards for encoding models and results in PMX and QSP

Thursday 14:40-16:00

IV-22Tatiana Yakovleva

A systems pharmacology model of SGLT2 and SGLT1 inhibition to understand mechanism and quantification of urinary glucose excretion after treatment with Dapagliflozin, Canagliflozin and Empagliflozin

Thursday 14:40-16:00

IV-23Paulo Teixeira

The Effect of Anthropometric Covariates on Clearance of Valproic Acid.

Thursday 14:40-16:00

IV-24Rob ter Heine

The influence of erythrocyte accumulation on everolimus pharmacokinetics and pharmacodynamics in cancer patients

Thursday 14:40-16:00

IV-25Adrien Tessier

Population Pharmacokinetic modelling and Pharmacogenetic analysis through a penalised regression approach for a molecule S

Thursday 14:40-16:00

IV-26Donato Teutonico

Whole-body PBPK/PD modelling of ciprofloxacin and its anti-bacterial activity

Thursday 14:40-16:00

IV-27Hoai-Thu Thai

Model-based drug development to support isatuximab dosing regimen selection in Phase II multiple myeloma patients

Thursday 14:40-16:00

IV-28Anders Thorsted

Toxicokinetics of Endotoxin and its Induction of Pro-Inflammatory Cytokines Tumor Necrosis Factor a and Interleukin-6

Thursday 14:40-16:00

IV-29Yingying Tian

Population pharmacokinetic analysis of everolimus in patients with solid tumors

Thursday 14:40-16:00

IV-30Huybrecht T'jollyn

Pharmacokinetics of galantamine in plasma and brain for different intranasal formulations: an experimental in vivo study

Thursday 14:40-16:00

IV-31Michel Tod

Comparison of the mechanistic static in vivo approach to a PBPK approach for prediction of metabolic drug-drug interactions.

Thursday 14:40-16:00

IV-32Bruna Gaelzer Silva Torres

Population Pharmacokinetic Modeling of Ciprofloxacin Free Lung Concentrations in Healthy and Pseudomonas aeruginosa Biofilm Infected Wistar Rats

Thursday 14:40-16:00

IV-33Elena Tosca

Evaluation of a PK/PD DEB-based model for tumor-in-host growth kinetics under anticancer treatment

Thursday 14:40-16:00

IV-34Mira Tout

Rituximab target-mediated elimination is influenced by both baseline antigenic burden and FCGR3A polymorphism in chronic lymphocytic leukemia

Thursday 14:40-16:00

IV-35Mirjam Trame

Development of a Mechanism Based Platform to Predict Cardiac Contractility and Hemodynamics in Conscious Dogs

Thursday 14:40-16:00

IV-36Iñaki F. Trocóniz

Markov Model for Lithium Compliance Assessment

Thursday 14:40-16:00

IV-37Max Tsai

Modelling of Pharmacokinetics and the Incidence of Adverse Events of the PDE-10A Inhibitor TAK-063

Thursday 14:40-16:00

IV-38

Assessment of DDI potential of ruxolitinib (INC424), a dual substrate of CYP3A4 and CYP2C9, using a verified PBPK model to support submissions to Health Authorities

Thursday 14:40-16:00

IV-39Moreno Ursino

Evaluating phase I studies in small populations when incorporating pharmacokinetic information

Thursday 14:40-16:00

IV-40Muhammad Usman

Population Pharmacokinetics of Meropenem in Elderly Patients: Dosing simulations based on Renal Function

Thursday 14:40-16:00

IV-41Vladimir Vainstein

Dose translation of a hematopoietic acute radiation syndrome protection agent (recombinant human Interleukin-12) to humans.

Thursday 14:40-16:00

IV-42Pyry Välitalo

A mathematical method assessing the informativeness of total test score on the basis of an item response theory model: A case study on pain in children

Thursday 14:40-16:00

IV-43Willem van den Brink

Finding underlying longitudinal patterns in pharmaco-metabolomics data

Thursday 14:40-16:00

IV-44Sven van Dijkman

Differentiation between Parkinson’s and Parkinson’s-like patients in MDS-UPDRS-based diagnosis

Thursday 14:40-16:00

IV-45Tamara van Donge

Evaluating biosimilarity of monoclonal antibodies: comparison of population approach nonlinear mixed effects models to standard non-compartmental analysis

Thursday 14:40-16:00

IV-46Michiel Van Esdonk

Development of a semi-population deconvolution method for the analysis of growth hormone profiles

Thursday 14:40-16:00

IV-47Coen van Hasselt

The proof is in the pee: Population asparagus urinary odor kinetics.

Thursday 14:40-16:00

IV-48

Competitive brain and body growth model

Thursday 14:40-16:00

IV-49Swantje Völler

Dose Recommendations for Recombinant Asparaginase in Children: A Population Pharmacokinetic Analysis

Thursday 14:40-16:00

IV-50Max von Kleist

Systems pharmacology pipeline to assess NRTI-efficacy for repurposing as pre-exposure prophylactic compounds against HIV-1 infection

Thursday 14:40-16:00

IV-51Camille Vong

Population Pharmacokinetics of Tofacitinib in Induction Studies for Moderate-to-Severe Ulcerative Colitis Patients

Thursday 14:40-16:00

IV-52Veronika Voronova

Investigation of the diabetes-related metabolic memory phenomenon using a quantitative systems pharmacology approach

Thursday 14:40-16:00

IV-53Ulrika Wählby Hamrén

Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423 following inhalation using different devices

Thursday 14:40-16:00

IV-55Siyuan Wang

An integrated PK/PD model to link the frequency of cancer-stem-like cells to tumor volume for sunitinib combined with dopamine in the treatment of drug-resistant breast cancer

Thursday 14:40-16:00

IV-56Sebastian Weber

Modeling Recurrent Safety Events in Drug Combinations using a Time-Varying Poisson Process

Thursday 14:40-16:00

IV-57Janak Wedagedera

Investigating the Importance of Considering Inter-correlations of Cytochrome P450 Enzyme Abundances in Human Liver When Predicting Drug-Drug Interactions

Thursday 14:40-16:00

IV-58Gustaf Wellhagen

Carbohydrate intake contribution to HbA1c

Thursday 14:40-16:00

IV-59Thomas Wendl

Computational Modelling of Personalized Hemodynamic Response to Valve Replacement Surgery in Heart Failure Patients

Thursday 14:40-16:00

IV-60Pawel Wiczling

A Bayesian approach for population pharmacokinetic modeling of dexmedetomidine during long-term infusion in critically ill pediatric patients.

Thursday 14:40-16:00

IV-61Rixt Wijma

Population pharmacokinetics of meropenem during intermittent and continuous infusion in healthy volunteers

Thursday 14:40-16:00

IV-62Jayson Wilbur

Zika microcephaly cutoffs revisited: A study of Non-parametric methods in fetal growth

Thursday 14:40-16:00

IV-63Julia Winkler

Population pharmacokinetics of lacosamide to support intravenous dose adaptation in children with epilepsy

Thursday 14:40-16:00

IV-64Jan-Georg Wojtyniak

A cancer cell cycle model to predict effects of combination therapy and different dosing schedules on cell cycle, tumor growth and therapy outcome

Thursday 14:40-16:00

IV-65Dan Wright

A population pharmacokinetic model for 51Cr EDTA, an isotopic biomarker for renal function: impact on carboplatin dosing.

Thursday 14:40-16:00

IV-66Xia Li

Population pharmacokinetics of multiple oral doses of alcohol in humans using blood and breath measures

Thursday 14:40-16:00

IV-67Gulbeyaz Yildiz Turkyilmaz

Investigating the ability of population PK models to characterize secondary exposure parameters

Thursday 14:40-16:00

IV-68

Pharmacokinetic Model for subconjunctival injection of bevacizumab in Rabbits.

Thursday 14:40-16:00

IV-69Seonghae Yoon

Population pharmacokinetic analysis of oxcarbazepine in patients with epilepsy

Thursday 14:40-16:00

IV-70Huixin Yu

Development of a pharmacokinetic model for pazopanib – a tyrosine kinase inhibitor used for the treatment of solid tumours

Thursday 14:40-16:00

IV-71Jurij Aguiar Zdovc

Pharmacokinetics of vancomycin in intensive-care patients

Thursday 14:40-16:00

IV-72Fan Zhang

Population pharmacokinetic modeling of lamotrigine in Chinese subjects

Thursday 14:40-16:00

IV-74Meng Zhaoling

Program-wise trial simulation assessing design and analysis options from proof of concept to dose ranging

Thursday 14:40-16:00

IV-75Chenguang Zhou

Semi-mechanistic multiple-analyte pharmacokinetic model for a THIOMAB antibiotic conjugate against Staphylococcus aureus in mouse, rat and monkey

Thursday 14:40-16:00

IV-76Li Zhu

Population Pharmacokinetic Modeling of Ulocuplumab, an anti-CXCR4 Monoclonal Antibody in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Multiple Myeloma

Thursday 14:40-16:00

IV-77Kirill Zhudenkov

A Markov Chain model to characterize cataract progression and disease burden in the Russian Federation

Thursday 14:40-16:00

IV-78Jochen Zisowsky

A Method to Perform PK-QT Analyses When Several Active Compounds or Metabolites Are Present

Thursday 14:40-16:00